var data={"title":"Lipiodol (ethiodized oil): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lipiodol (ethiodized oil): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7762?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lipiodol-ethiodized-oil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lipiodol (ethiodized oil): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24944459\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thromboembolism:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of ethiodized oil. Inject slowly with radiologic monitoring; do not exceed recommended dose.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">For intralymphatic, intrauterine, and selective hepatic intraarterial use only.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066596\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent, Radiologic Examination of GI Tract</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763521\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Use the smallest possible dose based on anatomical area to be visualized; dose varies with procedure. Refer to prescribing information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hysterosalpingography: </b> Inject in 2 mL increments into the endometrial cavity until tubal patency is observed; discontinue use if excessive discomfort develops. Reimage after 24 hours to determine if ethiodized oil has entered the peritoneal cavity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphography:</b>  <b>Note:</b> Inject into lymphatic vessel under radiological monitoring. Interrupt injection if patient experiences pain; discontinue injection if lymphatic blockage is present (to minimize entry into the venous circulation via lymphovenous channels) and/or as soon as ethiodized oil is radiographically evident in the thoracic duct (to minimize entry into the subclavian vein and pulmonary embolization). Obtain immediate postinjection images; reimage at 24 to 48 hours to evaluate nodal architecture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Unilateral lymphography of upper extremities: 2 to 4 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Unilateral lymphography of lower extremities: 6 to 8 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Penile lymphography: 2 to 3 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cervical lymphography: 1 to 2 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Selective hepatic intra-arterial injection:</b>  <b>Note:</b> Dose depends on tumor size, local blood flow in liver and tumor: Dosage range: 1.5 to 15 mL administered slowly under continuous radiologic monitoring; discontinue administration when stagnation or reflux is evident. Limit dose to the quantity required for adequate visualization; maximum total dose: 20 mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763520\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lipiodol-ethiodized-oil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lipiodol (ethiodized oil): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Use the smallest possible dose based on anatomical area to be visualized; dose varies with procedure. Refer to prescribing information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphography:</b>   1 to 6 mL according to area to be visualized; Maximum dose: 0.25 mL/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Inject into lymphatic vessel under radiological monitoring. Interrupt injection if patient experiences pain; discontinue injection if lymphatic blockage is present (to minimize entry into the venous circulation via lymphovenous channels) and/or as soon as ethiodized oil is radiographically evident in the thoracic duct (to minimize entry into the subclavian vein and pulmonary embolization). Obtain immediate postinjection images; reimage at 24 to 48 hours to evaluate nodal architecture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763522\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763523\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242258\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Iodine 37% (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763524\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ethiodized oil is a clear, pale yellow to amber colored oil; do not use if the color has darkened. Draw solution into a glass syringe and use promptly; discard any unused portion of Lipiodol. For intralymphatic, intrauterine, and selective hepatic intra-arterial use only. Route of administration varies by indication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hysterosalpingography:</i> Inject into endometrial cavity with fluoroscopic control.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lymphography:</i> Inject into a lymphatic vessel under radiologic guidance to prevent inadvertent venous administration or intravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Upper or lower extremities administration: Start injection into lymphatic channel at a rate not to exceed 0.2 mL/min; inject total dose in no less than 1.25 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Selective hepatic intra-arterial injection:</i> Inject amount slowly under continuous radiologic monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242259\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hysterosalpingography:</b>  For hysterosalpingography in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphography:</b> For lymphography in adult and pediatric patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Selective hepatic intra-arterial injection:</b> For imaging tumors in adults with known hepatocellular carcinoma (HCC)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24968651\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cerebral embolism, ischemia (hepatic; exacerbation), portal hypertension (exacerbation), pulmonary embolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic failure (exacerbation), hepatic insufficiency (irreversible), hepatic vein thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acute respiratory distress, allergic dermatitis, circulatory shock, cough, diarrhea, dyspnea, edema, fever, foreign body reaction, granuloma (including lipogranuloma), hepatic dysfunction (transitory), hypersensitivity, hyperthyroidism, hypothyroidism, iodism (headache, soreness of mouth and pharynx, coryza, and skin rash), liver decompensation, liver enzyme disorder, lymphangitis, lymphedema (exacerbation), nausea, pain, pelvic inflammatory disease (exacerbation), renal insufficiency, retinal vein occlusion, thrombophlebitis, thyroiditis, vomiting, wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242261\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ethiodized oil; patients with hyperthyroidism, traumatic injuries, recent hemorrhage or bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hysterosalpingography:</i> Pregnancy, acute pelvic inflammatory disease, marked cervical erosion, endocervicitis and intrauterine bleeding, in the immediate pre- or postmenstrual phase, or within 30 days of curettage or conization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lymphography:</i> Right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, radiation therapy to the examined area</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Selective hepatic intra-arterial injection:</i> Presence of dilated bile ducts unless external biliary drainage was performed before injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: Additional contraindications (not in US labeling):</i> Bronchography; IV, intrathecal, or intra-arterial (except for select use) use; acute parotiditis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763510\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious and life-threatening anaphylactoid and anaphylactic reactions with cardiovascular, respiratory, or cutaneous manifestations may occur. Avoid use in patients with a history of sensitivity to other iodine-based contrast media, bronchial asthma, or allergic disorders due to increased risk of hypersensitivity to ethiodized oil. Equipment for resuscitation and trained personnel experienced in handling emergencies should be immediately available. Most reactions occur within 30 minutes; delayed reactions may occur up to several days after administration. Monitor for &ge;30 minutes following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: <b>[US Boxed Warning]: Pulmonary and cerebral embolism may result from inadvertent intravascular injection or intravasation of ethiodized oil;</b> may occur immediately or a few hours to days after administration. Avoid use in patients with severely impaired lung function, cardiorespiratory failure, or right-sided cardiac overload. Radiological monitoring should be performed during injection; do not exceed the maximum recommended dose and rate of injection. To decrease the risk of pulmonary embolism during lymphography, obtain radiographic confirmation of intralymphatic injection and discontinue the procedure when ethiodized oil becomes visible in the thoracic duct or lymphatic obstruction is observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver disease: Use with caution in patients receiving hepatic intra-arterial administration; procedural risks include vascular complications and infections. Hepatic intra-arterial use may exacerbate: portal hypertension and cause variceal bleeds; hepatic ischemia and cause liver enzyme elevations, fever, and abdominal pain; hepatic failure and cause ascites and encephalopathy. Hepatic vein thrombosis, irreversible liver insufficiency, and death have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Hyperthyroidism or hypothyroidism may occur following administration of iodinated contrast media; use caution in patients at risk (eg, patients with latent hyperthyroidism, Hashimoto thyroiditis, or history of thyroid irradiation). Diagnostic tests may be affected for up to 2 years after lymphography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women: Hysterosalpingography: Prior to use exclude the presence of pregnancy, uterine bleeding, endocervicitis, acute pelvic inflammatory disease, the immediate pre- or postmenstrual phase, or within 30 days of curettage or conization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: For intralymphatic, intrauterine, and selective hepatic intra-arterial use only. Administer slowly with radiologic monitoring; do not exceed recommended dose. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24802026\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24802023\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95642&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242256\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763507\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted using the indicated routes of administration; however, adverse events have not been observed in animal reproduction studies following oral administration. Ethiodized oil use during pregnancy causes iodine transfer and may interfere with thyroid function of the fetus; brain damage and permanent hypothyroidism may occur. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763509\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ethiodized oil is excreted in breast milk. Breast-feeding is not recommended by the manufacturer; if breast-feeding is continued, thyroid function of the infant should be monitored.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763525\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function prior to administration and after administration in patients with a history of renal impairment; monitor for hypersensitivity reactions for at least 30 minutes following administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763513\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ethiodized oil is used as a radiopaque contrast agent composed of iodine combined with ethyl esters of fatty acids of poppy seed oil, primarily as ethyl monoiodostearate and ethyl diiodostearate. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24763514\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Duration: Hepatic: ~2 to 4 weeks after intra-arterial administration; retention in liver tumor is prolonged in hepatocellular carcinoma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25064104\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Lipiodol (AT, AU, BE, CH, CZ, DE, DK, EG, FR, GB, GR, HU, IE, IL, IT, KR, LU, NL, NZ, PH, PT, SI, TH, TR, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Lipiodol (ethiodized oil) [prescribing information]. Bloomington, IN: Guerbet; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipiodol (ethiodized oil) [product monograph]. Paris, France: Guerbet; July 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95642 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F24944459\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25066596\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F24763521\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F24763520\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24763522\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24763523\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242258\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24763524\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F242259\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24968651\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F242261\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F24763510\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24802026\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24802023\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F242256\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F24763507\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F24763509\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24763525\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24763513\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F24763514\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25064104\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/95642|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lipiodol-ethiodized-oil-pediatric-drug-information\" class=\"drug drug_pediatric\">Lipiodol (ethiodized oil): Pediatric drug information</a></li></ul></div></div>","javascript":null}